Search

Focuses on the potential from biomedical research done by Judah Folkman and colleagues at the Boston's Children's Hospital in Boston, Massachusetts. Endostatin and angiostatin as cancer treatments; Experiments with tumors in mice; Explanation of how the blood vessel inhibitors, or angiogenesis inhibitors, could work in the circulatory system; The problem of side effects; Mention of work by other researchers. INSET: For patients, an uncertain future.

Focuses on Dr. Moses Judah Folkman and his research to cure cancer. Reaction of the media to his discovery of a potential cancer treatment; The two drugs endostatin and angiostatin used in an experiment with mice; Background on Folkman; His interest in how blood vessels support tumor growth with capillaries; The basic fibroblast growth factor molecule; Isolation of the angiogenesis inhibitors. INSET: Turning the tables on tumors.

Healthy human tissue is highly regulated to maintain homeostasis. Secreted negative feedback factors that inhibit stem cell division and stem cell self-renewal play a fundamental role in establishing this control. The appearance of abnormal cancerous growth requires an escape from these regulatory mechanisms. In a previous study we found that for non-solid tumors if feedback inhibition on stem cell self-renewal is lost, but the feedback on the division rate is still intact, then the tumor dynamics are characterized by a relatively slow sub-exponential growth that we called inhibited growth. Here we characterize the cell dynamics of inhibited cancer growth by modeling feedback inhibition using Hill equations. We find asymptotic approximations for the growth rates of the stem cell and differentiated cell populations in terms of the strength of the inhibitory signal: stem cells grow as a power law t 1 / k + 1 , and the differentiated cells grow as t 1/ k , where k is the Hill coefficient in the feedback law regulating cell divisions. It follows that as the tumor grows, undifferentiated cells take up an increasingly large fraction of the population. Implications of these results for specific cancers including CML are discussed. Understanding how the regulatory mechanisms that continue to operate in cancer affect the rate of disease progression can provide important insights relevant to chronic or other slow progressing types of cancer. [ABSTRACT FROM AUTHOR]

The article discusses the impact of the high-fat diet for epilepsy on the brain. Topics discussed include the potential of the high-fat ketogenic diet in the prevention of the growth of cancer in people with brain tumours, the binding of the decanoic acid from frog cells to a molecule in the brain cells surface, and the statement of Robin Williams of Royal Holloway University of London that the chance of neuron firing is reduced by decanoic acid binding.

The article focuses on the announcement of Merck Serono SA on the completion of their Patient Enrollment for Cilengitide's Pivotal Phase III CENTRIC clinical study. Doctor Oliver Kisker states that the study completion may lead the firm a step closer on the evaluation of cilengitide's efficacy in patients with aggressive brain cancer, such as glioblastoma. It adds that cilengitide is believed to help in tumor growth control by targeting tumor cells directly and preventing tumor cell formation.

In addition to its documented antitumor effects, previous IN VITRO and IN VIVO infectivity experiments have shown that sulforaphane (SFN), an isothiocyanate compound found abundantly in broccoli and other cruciferous vegetables, inhibits the growth of the bacterial pathogen HELICOBACTER PYLORI. No recent evidence exists, however, on the possible microbial activity of SFN against a broader range of microorganisms, including those that may develop resistance to conventional antibiotics. The aim of this study was to determine the IN VITRO susceptibility patterns of SFN against a wide variety of bacterial and fungal pathogens. Sensitivity testing was done on 28 different microbial species using a modified Kirby-Bauer disk-diffusion method and results were interpreted based on guidelines established by the National Committee for Clinical Laboratory Standards. The broad-spectrum antibiotic, ceftriaxone (CTX), was used as a positive control for antimicrobial inhibition. It was found that 23 out of 28 different microbial species were inhibited by SFN with a minimal inhibitory concentration (MIC) ranging from 1 - 4 ?g/mL. Five pathogens - PSEUDOMONAS AERUGINOSA, 3 methicillin-resistant STAPHYLOCOCCUS AUREUS (MRSA) isolates and CANDIDA ALBICANS - were considered resistant to SFN, having MICs ? 16 - 32 ?g/mL. These findings suggest that, with the dual action of SFN against a select group of microorganisms and its ability to inhibit tumor growth, SFN (or the consumption of SFN-containing vegetables) might be especially helpful in preventing certain types of infections in both cancer and non-cancer patients. [ABSTRACT FROM AUTHOR]

The article discusses an experimental anti-cancer drug, called cabozantinib, that targets the tumor and prohibits its capacity to spread. Topics include an overview of cabozantinib's mechanism of action and several experimental clinical drug trials, including one led by Howard Scher at the Memorial Sloan-Kettering Cancer Center in New York, that found cabozantinib both prevented the growth of bone tumours and reduced their size in men with prostate cancer. INSET: RESPITE FOR FALTERING WONDER DRUGS.

Reports that the United States Food and Drug Administration approved a new type of cancer drug, Avastin, designed to starve tumors into submission. Impetus for the idea behind the drug; Results of Avastin studies.

The article focuses on topics related to medicine. It states Secretary of Health, Education and Welfare in the U.S. Elliot Richardson ordered the 1946 Hill-Burtin Act allowing a lower level of free medical services for the poor. It says that Harvard Medical School doctor M. Judah Folkman found tumor angiogenesis factor (TAF) as a wat to prevent tumor growth. It adds that New Zealand's Auckland Medical School doctor Colin Alexander theorized that chair sitting can be a cause of varicose veins.

The article discusses simple longevity that individual should start enjoying on a regular basis. It cites studies regarding the ability of walnuts to reduce prostate tumour growth and to prevent bone loss and notes the potential for curcumin to fight a variety inflammatory conditions including breast and lung cancers. The health benefits of kale, raisins, garlic, baby spinach, green tea, and blueberries are also highlighted.

The article focuses on the results of a research conducted on tumor growth and inhibition factors. It informs that the research is being conducted by Senesco Technologies Inc. and informs that the results from the completed non-clinical study of lenalidomide in a model of multiple myeloma show inhibition of tumor growth.

The article offers information on the inhibition of tumor growth by delivering micro ribonucleic acid (RNA) mimics. It mentions that the result was generated by Mirna Therapeutics Inc. in an animal model of lymphoma. It further informs about microRNA which includes its involvement in embryonic development, cellular pathways and immunity.

The article presents a research study which focuses on how to control TSC tumors. Study shows the effectiveness of depriving these nonmalignant tumors by 2-deoxyglucose restriction which hampers their growth and development. In addition, the restriction is capable of reducing tumor growth based on the experimental result conducted in mice. Information about glucose deprivation is also discussed.

The article focuses on the announcement of EMD Serono Inc. on the completion of their Patient Enrollment for Cilengitide's Pivotal Phase III CENTRIC clinical study. Doctor Oliver Kisker states that the study completion may lead the firm a step closer on the evaluation of cilengitide's efficacy in patients with aggressive brain cancer, such as glioblastoma. It adds that cilengitide is believed to help in tumor growth control by targeting tumor cells directly and preventing tumor cell formation.

For patients with colorectal cancer whose tumors overexpressed COX-2, regular aspirin use was associated with a lower risk of death related to colorectal cancer for about 12 years after initial diagnosis. [ABSTRACT FROM AUTHOR]

The article reports on the benefits of tea for human health. Tea, be it black, green, white or somewhere in between offers its own health perks. 10 ways to benefit from this age-old beverage are presented. Experts from leading American universities ranked tea second only to water as a healthful drink. Numerous studies support tea's role in preventing heart disease and researchers have investigated black and green teas' effects on cancer and found that these prevent tumor growth.

The article reports on the discovery that tumor cells may grow and spread using genetic programs normally associated with embryonic and fetal development. The possibility that gene-silencing therapy could be used to disrupt these programs in order to prevent the tumors from growing and spreading is noted.

The article focuses on the importance of polymer bubbles in the treatment of tumors. It notes that polymer bubbles could help slow the growth of tumors by transporting drugs that would break down in the body. The small interfering molecules of RNA (siRNA) can cure diseases like cancer by blocking protein production. Moreover, the Calando Pharmaceuticals Inc. in Pasadena, California is implementing human anti-cancer trials with a 70-nanometer polymer bubble that envelops the siRNA.

Presents a diagram describing how angiogenesis inhibitors, a new class of medications, attacks molecules that recruit blood vessels to feed tumors.

Mentions a drug that targets cancer cells, IMC-C225. Success of preliminary trials reported at an American Society of Clinical Oncology conference in spring 2000; How the drug works to shrink tumor growth.

Reports on a circular peptide of 10 amino acids which stops tumors from spreading and cuts off their blood supply. Action of the peptide against gelatinase A and B, two enzymes which help tumors migrate throught the bloodstream; Interference in the formation of new blood vessels to the tumor; Much less damaging side effects for the peptide than for other experimental drugs.

Discusses research which studied the way tea consumption inhibits cancer growth. Research by Morre and Morre, Purdue University; Benefits of green and black teas; Role of epigallocatechin gallate (EGCg) in all teas in cell growth control; Details about research methods; EGCg found to inhibit the activity of tumor-associated quinol oxidase (tNOX); Tea's antioxidant protection.

The article focuses on the potential of the tamoxifen drug to prevent the recurrence of breast cancer which has spread beyond the breast. According to Dr. Charles Hubay, the co-implementation of chemoteraphy and tamoxifen after mastectomy was more effective in delaying cancer recurrence than chemotherapy alone. It mentions that the drug has been implemented to breast cancer patients at an early cancer phase. It states that the drug is an antiestrogen agent that prevents the growth of estrogen-linked tumors which are associated to breast cancer. It discusses the study on the efficiency of the drug wherein the results show that cancer recurrence was observed to only about 10% of the patients who were also treated with tamoxifen.

The article focuses on the medical technology in the battle against cancer used at the Fermi National Accelerator Laboratory in Batavia, Illinois. It refers to Fermilab's weapon which uses high energy neutrons directed against certain tumors. In addition, high energy neutrons can be more effective than X rays since it penetrates through tumors and knocks out cancer cells. Moreover, neutron treatment is still highly experimental since its long-term effects have not yet been determined.

This section offers news briefs concerning research. Results of the catalytic system experimentation conducted by the Massachusetts Institute of Technology National Science Foundation researchers are reported. General Electric and Cornell University scientists have created an identification technique that can distinguish the metabolic activity of several bacteria strains. The Agriculture Research Service (ARS) of the U.S. Department of Agriculture learned that the camptothecin extract of the Camptotheca tree can halt tumor growth in laboratory animals.

The article highlights the health benefits of resveratrol, a substance found in the skins of red grapes and red wine. Studies revealed that resveratrol calms inflammation, enhances physical and mental performance, protects against tumor growth and balances blood sugar. It was also noted that resveratrol helps in preventing premature aging and disease.

Information about preclinical data results discussed at the Annual Meeting 2012 of American Association for Cancer Research (AACR) by Acceleron Pharma Inc. on effect of drug combinations with ACE-041 for the treatment of renal cell carcinoma (RCC). Topics include the response of VEGF-inhibitor sunitinib for anti angiogenesis therapies and effect of ACE-041 and sunitinib's combination on tumor perfusion.

The article reports on the result of a study which shows that it is possible to suppress the growth of brain tumours by treating the cytomegalovirus (CMV).

The article offers information on the study regarding the role of alpha-carotenoids in the health of people, which was conducted by doctor Chaoyang Li and colleagues from Division of Behavioral Surveillance of Center for Disease Control (CDC). It states that the study shows that people with high alpha-carotene level in their blood have low risk of having serious diseases such as cancer and cardiovascular disease. It adds that alpha-carotene inhibit proliferation of tumor cells.

An abstract of the article "Prolactinomas may have unusual presentations resulting from massive extrasellar tumor extension" by M.R.S. Berriel and others is presented.

The article reports on an announcement of Japanese pharmaceutical firm Eisai Co. Ltd. on signing of a license agreement with l biopharmaceutical products manufacturer HUYA Bioscience International LLC in order to make and market oral histone deacetylase (HDAC) inhibitor HBI-8000 in several areas such as Japan, Thailand and South Korea. Topics discussed include regulation of regulate tumor cell growth by the inhibitor; rights of the firm to make the inhibitor; and study related to epigenetics.

The article discusses reduced risk of malignant breast cancer for women who take extra virgin olive oil daily with Mediterranean diet compared to low-fat diet or Mediterranean diet with nuts, and quotes researchers that the oil contains antioxidants that kill cancer cells and stop tumor growth.

The article reports on the effectiveness of digoxin, a cardiac disease treatment, in preventing the prostate tumor pathogenesis. Several preclinical research have concluded that digoxin can possibly cure several cancers, particularly prostate cancer. Gregg L. Semenza from John Hopkins University School of Medicine has supported the claim. Moreover, several research are conducted to prove its potency.

The article reports on the significant impact of pazopanib, an oral angiogenesis inhibitor, on the tumor activity of patients with metastatic renal cell carcinoma. It notes that in a randomized study of patients with stable diseases, pazopanib shows a response rate of 34% in just 68 weeks. It notes that the treatment has demonstrated a durable anti tumor activity in advanced renal cell carcinoma.

The article presents an overview of the two main methods which are being explored for virotherapy, a technique which uses reproduced viruses to kill cancer tumors. A discussion of the benefits and mechanics of transcriptional targeting and another method which involves placing a tumor specific promoter next to one of an adenoviruses essential genes, is presented.

Reports on the effectiveness of flaxseed in slowing down breast cancer tumor growth. Experiment conducted by Paul Goss of the Princess Margaret Hospital.

The article highlights a study published in the "New England Journal of Medicine," which indicates that the drug crizotinib could halt tumor growth in adults with ROS1 non-small cell lung cancer (NSCLC) and therefore lead to better patient outcomes, while also causing fewer side effects than chemotherapy. It also notes that during the study period, fluorescence in-situ hybridization (FISH) testing was conducted to identify patients that are most likely to respond well to crizotinib therapy.

Explains why angiostatin and endostatin, which have been shown to reduce cancerous tumors in laboratory mice, are not available to cancer patients. Difficulties of mass-producing the substances; Necessity of designing and conducting tests of the substances function in humans; The costs and possible difficulties of the clinical trials.

The article discusses a study on naked mole rats that do not develop cancer conducted by Vera Gorbunova of the University of Rochester and colleagues and published in an issue of "Nature." It was noted that naked mole rats live for decades and produce complex sugar that prevents cells from clumping and forming tumors. Gorbunova and her team also exposed naked mole rat cells to viral protein that causes tumor growth in mice.

The article offers information on the compound identified by the researchers at the U.S. National Institutes of Health which helps in delaying formation of tumors in mice.

The article informs that scientists from the Pennsylvania State University in Pennsylvania have discovered a strategy for reactivating genes that can help in shrinking and killing of cancer tumors.

The article discusses research published in the journal "Science" by Reena Shakya of Columbia University which found that the tail end of the BRCA1 protein, which has been found to protect against breast cancer, contains amino acids which interact with DNA repair mechanisms and prevent tumors.

The article reports on the findings of a study conducted by Jason Abel and colleagues which reveals that early reduction in primary tumor (PT) size independently predicts better overall survival in patients with metastatic renal cell carcinoma (mRCC) treated with sunitinib.

The article discusses the invention of plastic beads, called QuadraSpheres, that fight cancer by preventing blood flow to tumors.

The article discusses a report in the August 19, 2009 issue of the "Journal of American Medical Association (JAMA)" by researcher Matthew Ellis and colleagues who enrolled 66 relapsed breast cancer patients who had received multiple estrogen-deprivation treatments. The focus of the study was the impact and potential use of estrogen on tumor growth and its prevention. Topics include an overview of the study results, such as the effect of estrogen on cancerous cell growth.

The article discusses research on the health significance of apple. It references a study published in "Nutrition." The study discovered that feeding mice with one apple a day reduced breast cancer tumor growth by 24 percent. It also found that adults who eat apple have 27 percent lower risk of metabolic syndrome.

The article reports on the findings of the study regarding tumor-suppressing proteins and beta cell growth, conducted by the Juvenile Diabetes Research Foundation International (JDRF) researchers at Stanford University in California. The researchers found that menin, a protein known to suppress tumors, plays a role in restraining insulin-producing beta cells from reproducing. In addition, menin was known in preventing cancer in the pancreas and other organs.

The article focuses on a study regarding the use of low-intensity, intermediate-frequency electric fields to combat an aggressive brain cancer known as glioblastoma multiforme (GBM). It is noted that the approach pinpoints tumors without invasive brain surgery and has more than doubled survival time in preliminary studies. Previous work has shown that if a 200 kilohertz field is applied to the microtubule spindle, which helps cell division, the spindle cannot form properly.

The article reports that microRNAs may help doctors predict the course and aggressiveness of pancreatic cancer and help in targeting the disease more effectively. miR-21 and miR-155 have been implicated in cancers and may, along with miR-196a-2, indicate a particularly aggressive form of the disease. Drugs could be formulated to interrupt the microRNAs associated with cancer.

The article reports that a new procedure to treat benign uterine fibroid tumors, uterine-artery embolization, is less effective than surgery in spite of its lower cost. Uterine-artery embolization involves inserting barriers to fibroid blood supply. Those patients receiving this kind of treatment were in the hospital for a shorter period of time, but had a higher rate of complications.